Vasculogenic Mimicry Triggers Early Recidivation and Resistance to Adjuvant Therapy in Esophageal Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Sep 11

PMID 39261780

Authors

Jue Chen

Yu Wang

Mengke Wu

Keke Yu

Junchi Liu

Jiayu Chang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the impact of vasculogenic mimicry (VM) and postoperative adjuvant therapy on the prognosis and survival of patients with esophageal squamous cell carcinoma (ESCC), as well as to assess whether VM affects the clinical benefit of postoperative adjuvant therapy.

Methods: This single-center retrospective analysis included patients who underwent radical surgery for ESCC, which was documented in the medical record system. The presence or absence of VM in surgical specimens was determined using double staining with PAS/CD31. Stratification was applied based on adjuvant therapy and VM status. Survival curves and COX modeling were used to analyze the impact of the presence or absence of VM on the benefit of adjuvant therapy and the survival prognosis of patients.

Results: VM-positive patients were more prone to postoperative recurrence and metastasis. VM was identified as an independent risk factor for progression-free survival (PFS) (p < 0.001, 95% CI:1.809-3.852) and overall survival (OS) (p < 0.001, 95% CI:1.603-2.786) in postoperative ESCC. Postoperative adjuvant therapy significantly prolonged PFS (p = 0.008) and OS time (p < 0.001) in patients with stage II and III ESCC, with concurrent chemoradiotherapy being the most effective. However, the presence of VM significantly reduced the benefits of postoperative adjuvant therapy (p < 0.001).

Conclusion: VM negatively impacts the prognosis of postoperative ESCC patients and reduces the efficacy of postoperative adjuvant therapy.

References

Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S . Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice. Endocrinology. 2008; 150(1):251-9. PMC: 5398428. DOI: 10.1210/en.2008-0044. View

Wang S, Gao X, Liu X, Gao S, Fan Y, Jiang Y . CD133+ cancer stem-like cells promote migration and invasion of salivary adenoid cystic carcinoma by inducing vasculogenic mimicry formation. Oncotarget. 2016; 7(20):29051-62. PMC: 5045377. DOI: 10.18632/oncotarget.8665. View

Scully S, Francescone R, Faibish M, Bentley B, Taylor S, Oh D . Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci. 2012; 32(37):12950-60. PMC: 3461581. DOI: 10.1523/JNEUROSCI.2017-12.2012. View

Yang J, Liao Y, Mai D, Xie P, Qiang Y, Zheng L . Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis. 2016; 19(2):191-200. DOI: 10.1007/s10456-016-9500-2. View

Ding Y, Qin Q, Yang Y, Sun X, Yang X, Zhu H . Improved sensitization effect of sunitinib in cancer cells of the esophagus under hypoxic microenviroment. Oncol Lett. 2017; 12(6):4671-4676. PMC: 5228423. DOI: 10.3892/ol.2016.5247. View

Sun H, Zhang D, Yao Z, Lin X, Liu J, Gu Q . Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. Cancer Biol Ther. 2017; 18(4):205-213. PMC: 5450737. DOI: 10.1080/15384047.2017.1294288. View

Deng W, Chen J, Xiao Z . ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy. Ann Surg Oncol. 2019; 26(Suppl 3):802-803. DOI: 10.1245/s10434-019-07728-7. View

Maniotis A, Folberg R, Hess A, Seftor E, Gardner L, Peer J . Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999; 155(3):739-52. PMC: 1866899. DOI: 10.1016/S0002-9440(10)65173-5. View

Huang M, Lin Y, Wang C, Deng L, Chen M, Assaraf Y . New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug Resist Updat. 2022; 64:100849. DOI: 10.1016/j.drup.2022.100849. View

10.

Liu Z, Chen H, Zheng L, Sun L, Shi L . Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023; 8(1):198. PMC: 10175505. DOI: 10.1038/s41392-023-01460-1. View

11.

Zheng J . Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 2012; 4(6):1151-1157. PMC: 3506713. DOI: 10.3892/ol.2012.928. View

12.

Liu Q, Zhao E, Geng B, Gao S, Yu H, He X . Tumor-associated macrophage-derived exosomes transmitting miR-193a-5p promote the progression of renal cell carcinoma via TIMP2-dependent vasculogenic mimicry. Cell Death Dis. 2022; 13(4):382. PMC: 9021253. DOI: 10.1038/s41419-022-04814-9. View

13.

Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo Y . Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Mol Cancer. 2021; 20(1):7. PMC: 7784348. DOI: 10.1186/s12943-020-01288-1. View

14.

Ni W, Yu S, Xiao Z, Zhou Z, Chen D, Feng Q . Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. Oncologist. 2021; 26(12):e2151-e2160. PMC: 8649038. DOI: 10.1002/onco.13914. View

15.

Dudley A, Griffioen A . Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. 2023; 26(3):313-347. PMC: 10105163. DOI: 10.1007/s10456-023-09876-7. View

16.

Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B . Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol. 2020; 13(1):19. PMC: 7071697. DOI: 10.1186/s13045-020-00858-6. View

17.

Hujanen R, Almahmoudi R, Karinen S, Nwaru B, Salo T, Salem A . Vasculogenic Mimicry: A Promising Prognosticator in Head and Neck Squamous Cell Carcinoma and Esophageal Cancer? A Systematic Review and Meta-Analysis. Cells. 2020; 9(2). PMC: 7072765. DOI: 10.3390/cells9020507. View

18.

Fan X, Huang J, Hu B, Zhou J, Chen L . Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer. J Cancer Res Clin Oncol. 2023; 149(11):8729-8741. DOI: 10.1007/s00432-023-04790-3. View

19.

Lin H, Chen L, Shang Q, Yuan Y, Yang Y . A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma. Int J Surg. 2020; 80:184-191. DOI: 10.1016/j.ijsu.2020.06.046. View

20.

Ajani J, DAmico T, Bentrem D, Chao J, Corvera C, Das P . Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(7):855-883. DOI: 10.6004/jnccn.2019.0033. View